Reversible lansoprazole-induced interstitial lung disease showing improvement after drug cessation.
Lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastric ulcers, H. pylori infection, gastroesophageal reflux disease or Zollinger-Ellison syndrome. Although lansoprazole is well known for its gastrointestinal and dermatologic adverse effects, mild pulmonary symptoms are also known to develop from taking this drug. There have been no reports about lansoprazole-induced interstitial lung disease. We report here a case of lansoprazole-induced interstitial lung disease that developed in a 66-year-old man.
Hwang
Kyu-won
KW
Department of Radiology, College of Medicine, Korea University, Guro Hospital, Seoul, Korea. wokhee@unitel.co.kr.
Woo
Ok Hee
OH
Yong
Hwan Seok
HS
Shin
Bong Kyung
BK
Shim
Jae Jeong
JJ
Kang
Eun-Young
EY
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects*; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D001706:Biopsy / Q000379:methods; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D064747:Lansoprazole; D008168:Lung / Q000473:pathology*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D020775:Thoracic Surgery, Video-Assisted; D014057:Tomography, X-Ray Computed
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole